^
    Back
    Association details:
    Biomarker:DDB1 overexpression
    Cancer:Multiple Myeloma
    Drug:thalidomide (TNF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    EXPRESSION SIGNIFICANCE OF CRL4-CRBN PROTEINS COMPLEX IN MULTIPLE MYELOMA PATIENTS TREATED WITH IMMUNOMODULATORY DRUGS.

    Published date:
    05/14/2020
    Excerpt:
    The high DDB1 expression, as the only one, was associated with longer OS of MM patients treated with thalidomide or lenalidomide (p=0.002).